- Home
- ABEO vs RCAT Comparison
ABEO vs RCAT Comparison
Compare ABEO & RCAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABEO
- RCAT
- Stock Information
- Founded
- ABEO 1974
- RCAT 2002
- Country
- ABEO United States
- RCAT United States
- Employees
- ABEO N/A
- RCAT N/A
- Industry
- ABEO Biotechnology: Pharmaceutical Preparations
- RCAT Wholesale Distributors
- Sector
- ABEO Health Care
- RCAT Industrials
- Exchange
- ABEO Nasdaq
- RCAT Nasdaq
- Market Cap
- ABEO 256.9M
- RCAT N/A
- IPO Year
- ABEO 1980
- RCAT 2017
- Fundamental
- Price
- ABEO $5.87
- RCAT $6.97
- Analyst Decision
- ABEO Strong Buy
- RCAT Buy
- Analyst Count
- ABEO 6
- RCAT 1
- Target Price
- ABEO $18.00
- RCAT $13.00
- AVG Volume (30 Days)
- ABEO 1.1M
- RCAT 9.6M
- Earning Date
- ABEO 08-11-2025
- RCAT 08-07-2025
- Dividend Yield
- ABEO N/A
- RCAT N/A
- EPS Growth
- ABEO N/A
- RCAT N/A
- EPS
- ABEO N/A
- RCAT N/A
- Revenue
- ABEO N/A
- RCAT $2,291,089.00
- Revenue This Year
- ABEO N/A
- RCAT $1,023.35
- Revenue Next Year
- ABEO $323.51
- RCAT $88.95
- P/E Ratio
- ABEO N/A
- RCAT N/A
- Revenue Growth
- ABEO N/A
- RCAT N/A
- 52 Week Low
- ABEO $3.93
- RCAT $1.13
- 52 Week High
- ABEO $7.32
- RCAT $15.27
- Technical
- Relative Strength Index (RSI)
- ABEO 48.09
- RCAT 47.70
- Support Level
- ABEO $5.68
- RCAT $6.69
- Resistance Level
- ABEO $5.93
- RCAT $7.23
- Average True Range (ATR)
- ABEO 0.26
- RCAT 0.41
- MACD
- ABEO -0.01
- RCAT -0.11
- Stochastic Oscillator
- ABEO 58.46
- RCAT 26.83
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.